News

Leerink Downgrades Eli Lilly and Company (LLY) to Market Perform From Outperform
Eli Lilly and Company (NYSE: LLY) is one of the top most profitable NYSE stocks to buy now. On August 7, Leerink downgraded ...
PMLive36m
Eli Lilly’s Mounjaro shown to provide cardiovascular protection in type 2 diabetes patients
Eli Lilly’s GIP/GLP-1 dual receptor agonist Mounjaro (tirzepatide) has demonstrated cardiovascular protection in a late-stage ...
Will Eli Lilly’s new GLP-1 pill work as well as the shot? Here's what we know now
Eli Lilly’s GLP-1 pill helped some participants lose up to 15% body weight. But is it as effective as the injection? Here's ...
Eli Lilly is giving Novo Nordisk a run for its money—so why is LLY stock still down today?
Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...
Eli Lilly: 50% Upside For LLY Stock?
In the wake of this sell-off, a critical question arises about whether LLY stock represents a buying opportunity.
Calls of the Day: Eli Lilly, E.L.F. Beauty and CRH PLC
Princess Diana’s Former Chef Reveals Exactly What He’d Serve Her, Prince William, and Prince Harry for Lunch ...
BioSpace7h
5 Oral Obesity Drugs Challenging Lilly’s Orforglipron
Here are five oral obesity candidates that, according to Mizuho’s Graig Suvannavejh, could change the weight loss game.
Eli Lilly Shares Plummet 14% Toward Worst Day In 25 Years—Here’s Why It’s Down
Eli Lilly on Thursday released data for its daily obesity pill, orforglipron, which found the medication helped obese or ...